A systematic review of cases of CNS demyelination following COVID-19 vaccination

Ismail Ibrahim Ismail 1, Sara Salama 2

Affiliations

15 January 2022

-

doi: 10.1016/j.jneuroim.2021.577765

Abstract

Background: Since the emergency use approval of different types of COVID-19 vaccines, several safety concerns have been raised regarding its early and delayed impact on the nervous system.

Objective: This study aims to systematically review the reported cases of CNS demyelination in association with COVID-19 vaccination, which has not been performed, to our knowledge.

Methods: A systematic review was performed by screening published articles and preprints of cases of CNS demyelination in association with COVID-19 vaccines in PubMed, SCOPUS, EMBASE, Google Scholar, Ovid and medRxiv databases, until September 30, 2021. This study followed PRISMA guidelines. Descriptive findings of reported cases were reviewed and stratified by demographic and clinical findings, diagnostic work-up, management, and overall outcome.

Results: A total of 32 cases were identified, with female predominance (68.8%) and median age of 44 years. Eleven cases were reported after Pfizer vaccine, 8 following AstraZeneca vaccine, 6 following Moderna, 5 following Sinovac/ Sinopharm vaccines, and one following each of Sputnik and Johnson&Johnson vaccines. The majority of cases (71.8%) occurred after the first dose of the vaccine, with neurological symptoms manifesting after a median of 9 days. The most common reported presentations were transverse myelitis (12/32) and MS-like pictures (first diagnosis or a relapse) in another 12/32 cases, followed by ADEM- like (5/32), and NMOSD- like (3/32) presentations. History of a previous immune-mediated disease was reported in 17/32 (53.1%) cases. The mRNA-based vaccines resulted in the greatest number of demyelinating syndromes (17/32), followed by viral vector vaccines (10/32), and inactivated vaccines (5/32). Most MS-like episodes (9/12) were triggered by mRNA-based vaccines, while TM occurred following both viral vector and mRNA-based vaccines. Management included high dose methylprednisolone, PLEX, IVIg, or a combination of those, with a favorable outcome in the majority of case; marked/complete improvement (25/32) or stabilized/ partial recovery in the remaining cases.

Conclusion: This systematic review identified few cases of CNS demyelination following all types of approved COVID-19 vaccines so far. Clinical presentation was heterogenous, mainly following the first dose, however, half of the reported cases had a history of immune-mediated disease. Favorable outcome was observed in most cases. We suggest long-term post-marketing surveillance for these cases, to assess for causality, and ensure the safety of COVID-19 vaccines.

Keywords: COVID-19; Demyelinating disease; Multiple sclerosis; SARS-CoV-2; Transverse myelitis; Vaccine.

Figures

Fig. 1 Flowchart of literature inclusion in accordance with PRISMA guidelines.

Fig. 1 Flowchart of literature inclusion in accordance with PRISMA guidelines.

Similar articles

CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.

Ebrahimi N, Mazdak M, Shaygannejad V, Mirmosayyeb O.Vaccine. 2023 Jan 27;41(5):1003-1008. doi: 10.1016/j.vaccine.2023.01.003. Epub 2023 Jan 6.PMID: 36635139 Free PMC article.

Association of CNS demyelination and COVID-19 infection: an updated systematic review.

Ismail II, Salama S.J Neurol. 2022 Feb;269(2):541-576. doi: 10.1007/s00415-021-10752-x. Epub 2021 Aug 12.PMID: 34386902 Free PMC article. Review.

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.

Ciampi E, Uribe-San-Martin R, Soler B, García L, Guzman J, Pelayo C, Jürgensen L, Guzman I, Vera F, Galleguillos L, Cárcamo C.Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.PMID: 35182880 Free PMC article.

Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience.

Monte G, Papetti L, Ferilli MAN, Ursitti F, Moavero R, Sforza G, Panella E, Tarantino S, Checchi MP, Vigevano F, Palma P, Valeriani M.Front Immunol. 2023 Jan 25;14:1106472. doi: 10.3389/fimmu.2023.1106472. eCollection 2023.PMID: 36761740 Free PMC article.

Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic review.

Ostovan VR, Sahraian MA, Karazhian N, Rostamihosseinkhani M, Salimi M, Marbooti H.Mult Scler Relat Disord. 2022 Oct;66:104032. doi: 10.1016/j.msard.2022.104032. Epub 2022 Jul 6.PMID: 35858499 Free PMC article. Review.

Cited by

The Potential Role of SARS-CoV-2 Infection and Vaccines in Multiple Sclerosis Onset and Reactivation: A Case Series and Literature Review.

Tavazzi E, Pichiecchio A, Colombo E, Rigoni E, Asteggiano C, Vegezzi E, Masi F, Greco G, Bastianello S, Bergamaschi R.Viruses. 2023 Jul 18;15(7):1569. doi: 10.3390/v15071569.PMID: 37515255 Free PMC article. Review.

New Onset Autoimmune Diseases after the Sputnik Vaccine.

Vera-Lastra O, Mora G, Lucas-Hernández A, Ordinola-Navarro A, Rodríguez-Chávez E, Peralta-Amaro AL, Medina G, Cruz-Dominguez MP, Jara LJ, Shoenfeld Y.Biomedicines. 2023 Jul 4;11(7):1898. doi: 10.3390/biomedicines11071898.PMID: 37509537 Free PMC article.

New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.

Harel T, Gorman EF, Wallin MT.Front Neurol. 2023 Jun 22;14:1099758. doi: 10.3389/fneur.2023.1099758. eCollection 2023.PMID: 37426444 Free PMC article. Review.

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.

Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, Karabudak R, Efendi H, Terzi M, Carra-Dalliere C, Durand-Dubief F, Thouvenot E, Ciron J, Zephir H, Bourre B, Casez O, De Seze J, Moreau T, Neau JP, Pelletier D, Kantarci O, Tutuncu M, Derache N, Bensa C, Louapre C, Benoit J, Landes-Chateau C, Lebrun-Frenay C.Mult Scler. 2023 Jun 15:13524585231179669. doi: 10.1177/13524585231179669. Online ahead of print.PMID: 37322880 Free PMC article.

Central nervous system demyelinating diseases: glial cells at the hub of pathology.

Coutinho Costa VG, Araújo SE, Alves-Leon SV, Gomes FCA.Front Immunol. 2023 May 16;14:1135540. doi: 10.3389/fimmu.2023.1135540. eCollection 2023.PMID: 37261349 Free PMC article. Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Achiron A., Dolev M., Menascu S., Zohar D.-N., Dreyer-Alster S., Miron S., et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult. Scler. 2021 May;27(6):864–870. - PMC - PubMed
  2.  
    1. Agmon-Levin N., Kivity S., Szyper-Kravitz M., Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus. 2009 Nov;18(13):1198–1204. - PubMed
  3.  
    1. Aharon-Maor A., Shoenfeld Y. The good, the bad and the ugly of vaccination. Isr. Med. Assoc. J. 2000 Mar;2(3):225–227. - PubMed
  4.  
    1. Alshararni Ali. Acute transverse Myelitis associated with COVID-19 vaccine: a case report. IJRPS. 2021 Jul 26;12(3):2083–2087.
  5.  
    1. Angum F., Khan T., Kaler J., Siddiqui L., Hussain A. The prevalence of autoimmune disorders in women: a narrative review. Cureus. 2020 May 13;12(5):e8094. doi: 10.7759/cureus.8094. https://www.cureus.com/articles/31952-the-prevalence-of-autoimmune-disor... [Internet]. [cited 2021 Sep 2]; Available from: (PMID: 32542149; PMCID: PMC7292717) - DOI - PMC - PubMed
  6.  
    1. Beh S.C., Greenberg B.M., Frohman T., Frohman E.M. Transverse Myelitis. Neurol. Clin. 2013 Feb;31(1):79–138. - PMC - PubMed
  7.  
    1. Cao L., Ren L., et al. Acta Neurol. Belg. 2021 Feb 1 doi: 10.1007/s13760-021-01608-2. [Internet]. [cited 2021 Sep 2]; Available from: - DOI - PMC - PubMed
  8.  
    1. CDC . US Department of Health and Human Services, CDC; Atlanata, GA: 2021. Vaccine Adverse Event Reporting System (VARES) Accessed August 15, 2021. 2021.
  9.  
    1. Chen S., Fan X.-R., He S., Zhang J.-W., Li S.-J. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol. Sci. 2021 Jun 29 doi: 10.1007/s10072-021-05427-4. [Internet]. [cited 2021 Sep 2]; Available from: - DOI - PMC - PubMed
  10.  
    1. von Csefalvay C. VAERS data reveals no increased risk of neuroautoimmune adverse events from COVID-19 vaccines [Internet] Inf. Dis. (except HIV/AIDS) 2021 Jun doi: 10.1101/2021.06.13.21258851. [cited 2021 Sep 2]. Available from: - DOI
  11.  
    1. De Martino M., Chiappini E., Galli L. Vaccines and autoimmunity. Int. J. Immunopathol. Pharmacol. 2013 Apr;26(2):283–290. - PubMed
  12.  
    1. Erdem N.Ş., Demirci S., Özel T., Mamadova K., Karaali K., Çelik H.T., et al. Acute transverse myelitis after inactivated COVID-19 vaccine. Ideggyogy Sz. 2021;74(7–8):273–276. - PubMed
  13.  
    1. Etemadifar M., Sigari A.A., Sedaghat N., Salari M., Nouri H. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Human Vacc. Immunotherap. 2021 May;20:1–3. - PMC - PubMed
  14.  
    1. Farez M.F., Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J. Neurol. 2011 Jul;258(7):1197–1206. - PubMed
  15.  
    1. Fitzsimmons W., Nance C.S. Sudden Onset of Myelitis after COVID-19 Vaccination: An Under-Recognized Severe Rare Adverse Event. SSRN J. 2021 https://www.ssrn.com/abstract=3841558 [Internet]. [cited 2021 Sep 2]; Available from:
  16.  
    1. Gao J.-J., Tseng H.-P., Lin C.-L., Shiu J.-S., Lee M.-H., Liu C.-H. Acute transverse myelitis following COVID-19 vaccination. Vaccines. 2021 Sep 10;9(9):1008. - PMC - PubMed
  17.  
    1. García-Grimshaw M., Ceballos-Liceaga S.E., Hernández-Vanegas L.E., Núñez I., Hernández-Valdivia N., Carrillo-García D.A., et al. Systemic and Neurologic Adverse Events Among 704,003 First-Dose Recipients of the Pfizer-Biontech (BNT162b2) mRNA COVID-19 Vaccine in Mexico. SSRN J. 2021;229:108786. doi: 10.1016/j.clim.2021.108786. https://www.ssrn.com/abstract=3816489 [Internet]. [cited 2021 Sep 2]; Available from: - DOI - PMC - PubMed
  18.  
    1. Goss A.L., Samudralwar R.D., Das R.R., Nath A. ANA investigates: neurological complications of COVID -19 vaccines. Ann. Neurol. 2021 May;89(5):856–857. - PMC - PubMed
  19.  
    1. Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, Kümpfel T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J. Neurol. [Internet]. 2021 Jun 11 [cited 2021 Sep 2]; Available from: doi:10.1007/s00415-021-10648-w. - DOI - PMC - PubMed
  20.  
    1. Helmchen C., Buttler G.M., Markewitz R., Hummel K., Wiendl H., Boppel T. Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2. J. Neurol. 2021 Jun 15 doi: 10.1007/s00415-021-10647-x. [Internet]. [cited 2021 Sep 2]; Available from: - DOI - PMC - PubMed
  21.  
    1. Hernández A.F., Calina D., Poulas K., Docea A.O., Tsatsakis A.M. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol. Rep. 2021;8:871–879. - PMC - PubMed
  22.  
    1. Hsiao Y.-T., Tsai M.-J., Chen Y.-H., Hsu C.-F. Acute transverse myelitis after COVID-19 vaccination. Medicina. 2021 Sep 25;57(10):1010. - PMC - PubMed
  23.  
    1. Ismail I.I., Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J. Neurol. 2021 Aug 12 doi: 10.1007/s00415-021-10752-x. [Internet]. [cited 2021 Sep 2]; Available from: - DOI - PMC - PubMed
  24.  
    1. Karussis D., Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun. Rev. 2014 Mar;13(3):215–224. - PubMed
  25.  
    1. Karussis D., Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun. Rev. 2014 Mar;13(3):215–224. - PubMed
  26.  
    1. Khan E., Shrestha A.K., Colantonio M.A., Liberio R.N., Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J. Neurol. 2021 Sep 5 doi: 10.1007/s00415-021-10785-2. [Internet]. [cited 2021 Oct 11]; Available from: - DOI - PMC - PubMed
  27.  
    1. Khayat-Khoei M., Bhattacharyya S., Katz J., Harrison D., Tauhid S., Bruso P., et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J. Neurol. 2021 Sep 4:1–14. - PMC - PubMed
  28.  
    1. Knoll M.D., Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021 Jan;397(10269):72–74. - PMC - PubMed
  29.  
    1. Ling Y., Zhong J., Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis. J. Med. Virol. 2021 Jul 26;93(12):6486–6495. doi: 10.1002/jmv.27203. PMID: 34264528; PMCID: PMC8426880. - DOI - PMC - PubMed
  30.  
    1. Lu L., Xiong W., Mu J., Zhang Q., Zhang H., Zou L., et al. The potential neurological effect of the COVID-19 vaccines: a review. Acta Neurol. Scand. 2021 Jul;144(1):3–12. - PMC - PubMed
  31.  
    1. Lu L., Xiong W., Mu J., Zhang Q., Zhang H., Zou L., et al. Neurological side effects of COVID-19 vaccines are rare. Acta Neurol. Scand. 2021 Jul;144(1):111–112. - PMC - PubMed
  32.  
    1. Mahase E. Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigated. BMJ. 2020 Sep;9:m3525. - PubMed
  33.  
    1. Mailand M.T., Frederiksen J.L. Vaccines and multiple sclerosis: a systematic review. J. Neurol. 2017 Jun;264(6):1035–1050. - PubMed
  34.  
    1. Malhotra H.S., Gupta P., Prabhu V., Kumar Garg R., Dandu H., Agarwal V. COVID-19 vaccination-associated myelitis. QJM: Int. J. Med. 2021 Mar 31;114(8):591–593. doi: 10.1093/qjmed/hcab069. PMID: 33787891; PMCID: PMC8083508. - DOI - PMC - PubMed
  35.  
    1. Maniscalco G.T., Manzo V., Di Battista M.E., Salvatore S., Moreggia O., Scavone C., et al. Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front. Neurol. 2021 Aug 10;12 - PMC - PubMed
  36.  
    1. Mathew T., John S.K. COVID-19 vaccine (ChAdOx1 nCoV-19 Corona virus vaccine (Recombinant)) – COVISHIELD related MS relapse. Neuroimmunol. Reports. 2021 Dec;1:100006.
  37.  
    1. McLean P., Trefts L. Transverse myelitis 48 hours after the administration of an mRNA COVID 19 vaccine. Neuroimmunol. Reports. 2021 Dec;1:100019.
  38.  
    1. Nagy A., Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput. Struct. Biotechnol. J. 2021;19:2508–2517. - PMC - PubMed
  39.  
    1. Ndwandwe D., Wiysonge C.S. COVID-19 vaccines. Curr. Opin. Immunol. 2021 Aug;71:111–116. - PMC - PubMed
  40.  
    1. Notghi A.A., Atley J., Silva M. Lessons of the month 1: longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination. Clin. Med. 2021 Sep;21(5):e535–e538. - PMC - PubMed
  41.  
    1. Ozgen Kenangil G., Ari B.C., Guler C., Demir M.K. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine. Acta Neurol. Belg. 2021 Aug;121(4):1089–1091. - PMC - PubMed
  42.  
    1. Pagenkopf C., Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J. Neuroimmunol. 2021 Sep;358:577606. - PMC - PubMed
  43.  
    1. Raknuzzaman M., Jannaty T., Hossain M.B., Saha B., Dey S.K., Shahidullah M. Post Covid19 vaccination acute disseminated encephalomyelitis: a case report in Bangladesh. Int. J. Med. Sci. Clin. Res. Stud. 2021;1(03):31–36.
  44.  
    1. Rinaldi V., Bellucci G., Romano A., Bozzao A., Salvetti M. ADEM after ChAdOx1 nCoV-19 vaccine: a case report. Mult. Scler. 2021 Sep;30 135245852110402. - PubMed
  45.  
    1. Román G.C., Gracia F., Torres A., Palacios A., Gracia K., Harris D. Acute transverse myelitis (ATM):clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222) Front. Immunol. 2021;12 - PMC - PubMed
  46.  
    1. Salemi S., D’Amelio R. Could autoimmunity be induced by vaccination? Int. Rev. Immunol. 2010 Jun;29(3):247–269. - PubMed
  47.  
    1. Seyed Ahadi M., Ghadiri F., Ahraian M.A., Naser Moghadasi A. Acute attack in a patient with multiple sclerosis 2 days after COVID vaccination: a case report. Acta Neurol. Belg. 2021 Aug 11 doi: 10.1007/s13760-021-01775-2. [Internet]. [cited 2021 Oct 11]; Available from: - DOI - PMC - PubMed
  48.  
    1. Somers E.C., Thomas S.L., Smeeth L., Hall A.J. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am. J. Epidemiol. 2009 Jan 6;169(6):749–755. - PubMed
  49.  
    1. Tahir N., Koorapati G., Prasad S., Jeelani H.M., Sherchan R., Shrestha J., et al. SARS-CoV-2 vaccination-induced transverse Myelitis. Cureus. 2021 Jul 25;13(7):e16624. https://www.cureus.com/articles/63667-sars-cov-2-vaccination-induced-tra... [Internet]. [cited 2021 Sep 2]; Available from: - PMC - PubMed
  50.  
    1. Vegezzi E., Ravaglia S., Buongarzone G., Bini P., Diamanti L., Gastaldi M., et al. Acute myelitis and ChAdOx1 nCoV-19 vaccine: casual or causal association? J. Neuroimmunol. 2021 Oct;359:577686. - PMC - PubMed
  51.  
    1. Velikova T., Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol. Int. 2021 Mar;41(3):509–518. - PMC - PubMed
  52.  
    1. Vera-Lastra O., Medina G., Cruz-Dominguez M.D.P., Jara L.J., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum. Expert. Rev. Clin. Immunol. 2013 Apr;9(4):361–373. - PubMed
  53.  
    1. Vogrig A., Janes F., Gigli G.L., Curcio F., Negro I.D., D’Agostini S., et al. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin. Neurol. Neurosurg. 2021 Sep;208:106839. - PMC - PubMed
  54.  
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan;397(10269):99–111. - PMC - PubMed
  55.  
    1. Watad A., De Marco G., Mahajna H., Druyan A., Eltity M., Hijazi N., et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021 Apr 29;9(5):435. - PMC - PubMed
  56.  
    1. World Health Organisation WHO Coronavirus Disease (COVID-19) Dashboard. [Internet] 2021. https://covid19.who.int/ [cited 2021 Sep 1]. Available from:
  57.  
    1. Wraith D.C., Goldman M., Lambert P.-H. Vaccination and autoimmune disease: what is the evidence? Lancet. 2003 Nov;362(9396):1659–1666. - PubMed

Page Navigation